Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
type
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1729339

	registered interest
	date	12/09/2024
	answering body	Department for Work and Pensions
	answering dept id	29
	answering dept short name	Work and Pensions
	answering dept sort name	Work and Pensions
	hansard heading	State Retirement Pensions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Work and Pensions, what steps her Department is taking to ensure that (a) old and (b) new State Pension recipients are equally financially supported.
	tabling member constituency	Dwyfor Meirionnydd
	tabling member printed	Liz Saville Roberts
	type	WrittenParliamentaryQuestion
	uin	5609
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>We are absolutely committed to supporting pensioners and giving them the dignity and security they deserve in retirement.</p><p> </p><p>Under both the old and new State Pension systems, the amount people receive varies according to their National Insurance record.</p><p> </p><p>Over the course of this Parliament we expect over 12 million pensioners are likely to see their new State Pensions increase by £1700 as a result of our commitment to the Triple Lock.</p> answering member constituency Wycombe answering member printed Emma Reynolds question first answered 08/10/2024 14:00:33 answering member 4077 label Biography information for Emma Reynolds
	tabling member	4521 label Biography information for Liz Saville Roberts

1729340

	registered interest
	date	12/09/2024
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Parking Offences: Automatic Number Plate Recognition
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, pursuant to the Answer of 2 September 2024 to Question 2438, whether her Department has issued guidance on the use of automatic number plate recognition by local authorities as a parking enforcement tool.
	tabling member constituency	Faversham and Mid Kent
	tabling member printed	Helen Whately
	type	WrittenParliamentaryQuestion
	uin	5612
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Department does not issue specific guidance pertaining to the use of automatic number plate recognition (ANPR). ANPR technology is not certified for the purpose of civil enforcement of road traffic contraventions by local authorities.</p><p> </p><p>In contrast to the restrictions placed on local authorities, which cannot use ANPR technology to enforce a parking charge once a vehicle has left the car park, private operators are allowed to use ANPR technology as the sole means of enforcement for parking on controlled land.</p> answering member constituency Nottingham South answering member printed Lilian Greenwood question first answered 08/10/2024 16:14:09 answering member 4029 label Biography information for Lilian Greenwood
	tabling member	4527 label Biography information for Helen Whately

1729343

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many times the Pharmacy First service has been used in each month since its launch.
	tabling member constituency	Harborough, Oadby and Wigston
	tabling member printed	Neil O'Brien
	type	WrittenParliamentaryQuestion
	uin	5649
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Pharmacy First was launched on 31 January 2024, and the overall service consists of three core elements:</p><ul><li>clinical pathways, a new element;</li><li>urgent medicine supply, previously commissioned as the Community Pharmacist Consultation Service; and</li><li>National Health Service referrals to Community Pharmacy for minor illness, previously commissioned as the Community Pharmacist Consultation Service.</li></ul><p><br> The following table shows a breakdown of all claimed consultations from February to May 2024:</p><table><tbody><tr><td><p> </p></td><td colspan="3"><p>Number of claimed consultations</p></td></tr><tr><td><p> </p></td><td><p>Clinical pathways</p></td><td><p>Urgent medicine supply</p></td><td><p>Minor illness</p></td></tr><tr><td><p>February 2024</p></td><td><p>125,275</p></td><td><p>78,831</p></td><td><p>137,396</p></td></tr><tr><td><p>March 2024</p></td><td><p>144,389</p></td><td><p>95,789</p></td><td><p>131,715</p></td></tr><tr><td><p>April 2024</p></td><td><p>153,646</p></td><td><p>90,851</p></td><td><p>126,193</p></td></tr><tr><td><p>May 2024</p></td><td><p>168,447</p></td><td><p>110,710</p></td><td><p>127,706</p></td></tr><tr><td><p>Total</p></td><td><p>591,757</p></td><td><p>376,181</p></td><td><p>523,010</p></td></tr></tbody></table> answering member constituency Aberafan Maesteg answering member printed Stephen Kinnock question first answered 08/10/2024 15:20:00 answering member 4359 label Biography information for Stephen Kinnock
	tabling member	4679 label Biography information for Neil O'Brien

1729345

	registered interest
	date	12/09/2024
	answering body	Department for Environment, Food and Rural Affairs
	answering dept id	13
	answering dept short name	Environment, Food and Rural Affairs
	answering dept sort name	Environment, Food and Rural Affairs
	hansard heading	Government Departments: Food
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Environment, Food and Rural Affairs, if he will make it his policy to encourage Government Departments in Whitehall to prioritise the (a) procurement and (b) purchase of British produced (i) food and (ii) drink.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	type	WrittenParliamentaryQuestion
	uin	5532
	answer	answer is ministerial correction date of answer 07/10/2024 answer text <p>As set out in the manifesto, we have an ambition to supply half of all food and drink into the public sector from local, British producers or those certified to higher environmental standards, whilst remaining in line with our World Trade Organization and domestic procurement obligations.</p> answering member constituency Cambridge answering member printed Daniel Zeichner question first answered 07/10/2024 09:17:08 answering member 4382 label Biography information for Daniel Zeichner
	tabling member	350 label Biography information for Sir John Hayes

1729346

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to reduce prescriptions for anti-depressant medication.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5539
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Overprescribing can be addressed by taking a shared decision-making approach and optimising a person's medicines, and by ensuring that patients are prescribed the right medicines at the right time, in the right doses.</p><p>NHS England has published Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action. It aims to further reduce inappropriate prescribing of medicines which can cause withdrawal, such as anti-depressants, where they may no longer be the most clinically appropriate treatment for patients and alternatives to medicines may be equally or more appropriate. More information on the framework is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/" target="_blank">https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/</a></p><p>NHS England provides support to integrated care boards (ICBs) and primary care as the Framework is implemented. For example, there is National medicines optimisation opportunities for the NHS, which includes an opportunity for addressing inappropriate antidepressant prescribing, with more information available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/" target="_blank">https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/</a></p><p>There is also Specialist Pharmacy Service advice on deprescribing antidepressants, for which more information is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/" target="_blank">https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/</a></p><p>There is annual investment of £2.3 billion until 2024 in mental health services and NHS Talking Therapies for anxiety and depression (which delivered 670,000 courses of treatment in 2022/23). More information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23</a></p><p>There is also a national programme to ensure social prescribing is an option for patients, as well as funding for social prescribers through the Additional Roles Reimbursement Scheme (ARRS). More information is available at the following links:</p><p><a href="https://www.england.nhs.uk/personalisedcare/social-prescribing/" target="_blank">https://www.england.nhs.uk/personalisedcare/social-prescribing/</a></p><p><a href="https://www.england.nhs.uk/gp/expanding-our-workforce/" target="_blank">https://www.england.nhs.uk/gp/expanding-our-workforce/</a></p><p>There is also support for delivering Structured Medication Reviews, including those on medicines associated with dependence and withdrawal symptoms), via: Health Innovation Network training to help build GP and prescribing health care professionals' confidence in, and understanding of, the complex issues surrounding stopping inappropriate medicines safely. Guidance is also published by NHS England on Structured Medication Review and Medicines Optimisation, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/" target="_blank">https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/</a></p><p>Offering treatments that are not medicines is also key to addressing overprescribing. Many other initiatives delivered across the National Health Service contribute towards this.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 5540 5544 question first answered 08/10/2024 13:22:18 answering member 4444 label Biography information for Karin Smyth
	tabling member	1447 label Biography information for Andrew Rosindell

1729347

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants: Prescriptions
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to publish guidance to GPs on reducing prescriptions for anti-depressant medication.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5540
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Overprescribing can be addressed by taking a shared decision-making approach and optimising a person's medicines, and by ensuring that patients are prescribed the right medicines at the right time, in the right doses.</p><p>NHS England has published Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action. It aims to further reduce inappropriate prescribing of medicines which can cause withdrawal, such as anti-depressants, where they may no longer be the most clinically appropriate treatment for patients and alternatives to medicines may be equally or more appropriate. More information on the framework is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/" target="_blank">https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/</a></p><p>NHS England provides support to integrated care boards (ICBs) and primary care as the Framework is implemented. For example, there is National medicines optimisation opportunities for the NHS, which includes an opportunity for addressing inappropriate antidepressant prescribing, with more information available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/" target="_blank">https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/</a></p><p>There is also Specialist Pharmacy Service advice on deprescribing antidepressants, for which more information is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/" target="_blank">https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/</a></p><p>There is annual investment of £2.3 billion until 2024 in mental health services and NHS Talking Therapies for anxiety and depression (which delivered 670,000 courses of treatment in 2022/23). More information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23</a></p><p>There is also a national programme to ensure social prescribing is an option for patients, as well as funding for social prescribers through the Additional Roles Reimbursement Scheme (ARRS). More information is available at the following links:</p><p><a href="https://www.england.nhs.uk/personalisedcare/social-prescribing/" target="_blank">https://www.england.nhs.uk/personalisedcare/social-prescribing/</a></p><p><a href="https://www.england.nhs.uk/gp/expanding-our-workforce/" target="_blank">https://www.england.nhs.uk/gp/expanding-our-workforce/</a></p><p>There is also support for delivering Structured Medication Reviews, including those on medicines associated with dependence and withdrawal symptoms), via: Health Innovation Network training to help build GP and prescribing health care professionals' confidence in, and understanding of, the complex issues surrounding stopping inappropriate medicines safely. Guidance is also published by NHS England on Structured Medication Review and Medicines Optimisation, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/" target="_blank">https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/</a></p><p>Offering treatments that are not medicines is also key to addressing overprescribing. Many other initiatives delivered across the National Health Service contribute towards this.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 5539 5544 question first answered 08/10/2024 13:22:18 answering member 4444 label Biography information for Karin Smyth
	tabling member	1447 label Biography information for Andrew Rosindell

1729348

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants: Research
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will take steps to provide funding for medical research into alternatives to antidepressant medication.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5541
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Department funds research through the National Institute for Health and Care Research (NIHR). The NIHR funds an extensive portfolio of mental health research, including a number of investments focused on alternatives to antidepressant medication. For example, the NIHR Oxford Health Biomedical Research Centre has a dedicated research theme on depression therapeutics and human neurocognitive models of antidepressant action. Additionally, the NIHR invested £1.1 million in a randomised controlled trial to examine if it is feasible, safe, and effective to use psilocybin to treat people with treatment-resistant depression, which was supported by the NIHR King’s Clinical Research Facility and the NIHR Maudsley Biomedical Research Centre. The study was completed in February 2024 and the full results will be published following peer review. The NIHR welcomes funding applications for research into any aspect of human health, including alternatives to antidepressant medication.</p> answering member constituency Gorton and Denton answering member printed Andrew Gwynne question first answered 08/10/2024 14:52:29 answering member 1506 label Biography information for Andrew Gwynne
	tabling member	1447 label Biography information for Andrew Rosindell

1729349

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants: Side Effects
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help treat people who have had adverse reactions to antidepressant medication including to (a) selective serotonin reuptake inhibitors and (b) serotonin and norepinephrine reuptake inhibitors.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5542
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency approved Patient Information Leaflets outline the details of possible adverse reactions associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors, and highlight when the advice of a healthcare professional should be sought for specific serious adverse reactions.</p><p>People who are concerned about adverse reactions to antidepressants should speak to a healthcare professional. Suspected adverse reactions to medicines, including antidepressant medication, can be reported through the Yellow Card Scheme, which is the system for recording adverse reactions suspected to be associated with medicines and medical devices in the United Kingdom.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 08/10/2024 15:03:57 answering member 4444 label Biography information for Karin Smyth
	tabling member	1447 label Biography information for Andrew Rosindell

1729350

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants: Side Effects
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to treat people who have (a) post-acute withdrawal syndrome and (b) post-SSRI sexual dysfunction after taking anti-depressant medication.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5543
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) approved product information outlines the details of possible adverse reactions associated with each medicine. Whilst post-acute withdrawal syndrome is not currently recognised as being associated with antidepressant use, the product information for the most commonly prescribed antidepressants contain advice about the risk of withdrawal reactions associated with antidepressant use, and advises users not to stop these types of medication abruptly.</p><p>The product information for some antidepressants contains advice that they can be associated with sexual dysfunction where symptoms continue despite stopping the antidepressant. An expert working group of the Commission on Human Medicines has been established to review how the risk of sexual dysfunction, where symptoms may continue, is communicated to patients. Separately, a review of the communication of the risk of withdrawal reactions in the product information will be taken forward in the MHRA’s project, to improve the information supplied with known dependency-forming medicines. Patients can visit either their general practice, or a sexual health clinic, for support with erectile dysfunction.</p> answering member constituency Bristol South answering member printed Karin Smyth question first answered 08/10/2024 15:04:58 answering member 4444 label Biography information for Karin Smyth
	tabling member	1447 label Biography information for Andrew Rosindell

1729351

	registered interest
	date	12/09/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Antidepressants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if he will publish guidance for (a) GPs and (b) psychiatrists on (i) safely deprescribing and (ii) providing alternative medications for patients on antidepressant medications.
	tabling member constituency	Romford
	tabling member printed	Andrew Rosindell
	type	WrittenParliamentaryQuestion
	uin	5544
	answer	answer is ministerial correction date of answer 08/10/2024 answer text <p>Overprescribing can be addressed by taking a shared decision-making approach and optimising a person's medicines, and by ensuring that patients are prescribed the right medicines at the right time, in the right doses.</p><p>NHS England has published Optimising personalised care for adults prescribed medicines associated with dependence or withdrawal symptoms: framework for action. It aims to further reduce inappropriate prescribing of medicines which can cause withdrawal, such as anti-depressants, where they may no longer be the most clinically appropriate treatment for patients and alternatives to medicines may be equally or more appropriate. More information on the framework is available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/" target="_blank">https://www.england.nhs.uk/long-read/optimising-personalised-care-for-adults-prescribed-medicines-associated-with-dependence-or-withdrawal-symptoms/</a></p><p>NHS England provides support to integrated care boards (ICBs) and primary care as the Framework is implemented. For example, there is National medicines optimisation opportunities for the NHS, which includes an opportunity for addressing inappropriate antidepressant prescribing, with more information available at the following link:</p><p><a href="https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/" target="_blank">https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/</a></p><p>There is also Specialist Pharmacy Service advice on deprescribing antidepressants, for which more information is available at the following link:</p><p><a href="https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/" target="_blank">https://www.sps.nhs.uk/articles/deprescribing-of-antidepressants-for-depression-and-anxiety/</a></p><p>There is annual investment of £2.3 billion until 2024 in mental health services and NHS Talking Therapies for anxiety and depression (which delivered 670,000 courses of treatment in 2022/23). More information is available at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/nhs-talking-therapies-for-anxiety-and-depression-annual-reports/2022-23</a></p><p>There is also a national programme to ensure social prescribing is an option for patients, as well as funding for social prescribers through the Additional Roles Reimbursement Scheme (ARRS). More information is available at the following links:</p><p><a href="https://www.england.nhs.uk/personalisedcare/social-prescribing/" target="_blank">https://www.england.nhs.uk/personalisedcare/social-prescribing/</a></p><p><a href="https://www.england.nhs.uk/gp/expanding-our-workforce/" target="_blank">https://www.england.nhs.uk/gp/expanding-our-workforce/</a></p><p>There is also support for delivering Structured Medication Reviews, including those on medicines associated with dependence and withdrawal symptoms), via: Health Innovation Network training to help build GP and prescribing health care professionals' confidence in, and understanding of, the complex issues surrounding stopping inappropriate medicines safely. Guidance is also published by NHS England on Structured Medication Review and Medicines Optimisation, which is available at the following link:</p><p><a href="https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/" target="_blank">https://www.england.nhs.uk/publication/structured-medication-reviews-and-medicines-optimisation/</a></p><p>Offering treatments that are not medicines is also key to addressing overprescribing. Many other initiatives delivered across the National Health Service contribute towards this.</p> answering member constituency Bristol South answering member printed Karin Smyth grouped question UIN 5539 5540 question first answered 08/10/2024 13:22:18 answering member 4444 label Biography information for Karin Smyth
	tabling member	1447 label Biography information for Andrew Rosindell